Protalix BioTherapeutics, Inc.
PLX
$1.93
$0.021.05%
AMEX
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -48.90% | 14.01% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -48.90% | 14.01% | |||
| Cost of Revenue | 182.41% | 41.81% | |||
| Gross Profit | -251.00% | -2.67% | |||
| SG&A Expenses | 20.38% | 11.62% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -12.34% | 8.52% | |||
| Operating Income | -318.58% | 81.83% | |||
| Income Before Tax | -313.31% | 238.73% | |||
| Income Tax Expenses | 727.59% | -123.34% | |||
| Earnings from Continuing Operations | -333.72% | 1,335.98% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -333.72% | 1,335.98% | |||
| EBIT | -318.58% | 81.83% | |||
| EBITDA | -270.64% | 63.38% | |||
| EPS Basic | -333.00% | 1,314.29% | |||
| Normalized Basic EPS | -311.86% | 233.96% | |||
| EPS Diluted | -333.00% | 1,385.00% | |||
| Normalized Diluted EPS | -316.76% | 239.22% | |||
| Average Basic Shares Outstanding | 0.29% | 0.79% | |||
| Average Diluted Shares Outstanding | -1.61% | -0.56% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||